儿童肿瘤学组 2013 年研究蓝图：软组织肉瘤。
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.
机构信息
Seattle Children's Hospital, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, WA 98015, USA.
出版信息
Pediatr Blood Cancer. 2013 Jun;60(6):1001-8. doi: 10.1002/pbc.24435. Epub 2012 Dec 19.
Abstract
In the US, approximately 850-900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high-risk RMS, and a biologically designed non-cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF-1R for children with RMS and VEGF for children with non-RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition.
摘要
在美国，每年大约有 850-900 名儿童被诊断患有软组织肉瘤（STS）。最近儿童肿瘤学组（COG）临床试验的主要发现包括：横纹肌肉瘤（RMS）低风险患者的治疗安全减少，FOXO1 融合作为预后因素得到验证，高危 RMS 患者的结果略有改善，以及针对儿科硬纤维瘤的生物学设计的非细胞毒性治疗。计划进行的 2 期试验包括针对 RMS 患儿的 VEGF/PDGF、mTOR 和 IGF-1R 的靶向药物，以及针对非 RMS STS（NRSTS）患儿的 VEGF。对于 RMS，COG 的 3 期试验可能会探索 VEGF/mTOR 抑制或化疗间隔压缩。对于 NRSTS，COG 的 3 期试验将探索 VEGF 抑制。
相似文献
1
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.儿童肿瘤学组 2013 年研究蓝图：软组织肉瘤。
Pediatr Blood Cancer. 2013 Jun;60(6):1001-8. doi: 10.1002/pbc.24435. Epub 2012 Dec 19.
2
Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas.儿童肿瘤学组 2023 年研究蓝图：软组织肉瘤。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30556. doi: 10.1002/pbc.30556. Epub 2023 Jul 10.
3
Soft tissue sarcomas in children.儿童软组织肉瘤。
Indian J Pediatr. 2012 Jul;79(7):936-42. doi: 10.1007/s12098-011-0560-4. Epub 2011 Sep 21.
4
Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children's Oncology Group.入组 2 期合作组临床试验的复发或难治性非横纹肌肉瘤软组织肉瘤患者的结局：来自儿童肿瘤协作组的报告。
Cancer. 2024 Jul 15;130(14):2493-2502. doi: 10.1002/cncr.35276. Epub 2024 Mar 12.
5
Non-rhabdomyosarcoma soft-tissue sarcoma.非横纹肌肉瘤软组织肉瘤。
Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28279. doi: 10.1002/pbc.28279.
6
Lymph node metastases in paediatric and young adult patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Findings from Children's Oncology Group (COG) study ARST0332.儿童肿瘤学组（COG）研究 ARST0332 显示，儿童和青年非横纹肌肉瘤软组织肉瘤（NRSTS）患者存在淋巴结转移：
Eur J Cancer. 2023 Feb;180:89-98. doi: 10.1016/j.ejca.2022.11.014. Epub 2022 Nov 25.
7
Children's Oncology Group's 2013 blueprint for research: bone tumors.儿童肿瘤学组 2013 年研究蓝图：骨肿瘤。
Pediatr Blood Cancer. 2013 Jun;60(6):1009-15. doi: 10.1002/pbc.24429. Epub 2012 Dec 19.
8
Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).儿童非横纹肌肉瘤软组织肉瘤：欧洲儿科软组织肉瘤研究组（EpSSG）的治疗标准与建议
Cancer Manag Res. 2022 Sep 23;14:2885-2902. doi: 10.2147/CMAR.S368381. eCollection 2022.
9
Soft tissue sarcoma in children: prognosis and management.儿童软组织肉瘤：预后与管理
Paediatr Drugs. 2002;4(1):21-8. doi: 10.2165/00128072-200204010-00003.
10
Clinical features and outcomes of infantile soft-tissue sarcoma: A multicenter retrospective study in Beijing.婴儿软组织肉瘤的临床特征和结局：北京多中心回顾性研究。
J Cancer Res Ther. 2023 Aug;19(4):876-880. doi: 10.4103/jcrt.jcrt_1950_22.
引用本文的文献
1
Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy.通过联合原发性嵌合抗原受体自然杀伤细胞（CAR NK细胞）和放射疗法精准靶向横纹肌肉瘤。
J Immunother Cancer. 2025 Jul 7;13(7):e011330. doi: 10.1136/jitc-2024-011330.
2
A Rare Presentation of Sclerosing-Type Rhabdomyosarcoma in an Underserved Patient: A Case Report.硬化型横纹肌肉瘤在医疗服务不足患者中的罕见表现：一例病例报告
Cureus. 2025 Apr 11;17(4):e82110. doi: 10.7759/cureus.82110. eCollection 2025 Apr.
3
A Report of Two Cases of Embryonal Rhabdomyosarcoma: Diagnostic Insights From Pathology.两例胚胎性横纹肌肉瘤报告：病理学诊断见解
Cureus. 2025 Mar 12;17(3):e80498. doi: 10.7759/cureus.80498. eCollection 2025 Mar.
4
Clinicopathological analysis of 13 patients with embryonal rhabdomyosarcoma of the female reproductive system in the Chinese population.中国人群中13例女性生殖系统胚胎性横纹肌肉瘤患者的临床病理分析
Front Oncol. 2025 Mar 14;15:1546607. doi: 10.3389/fonc.2025.1546607. eCollection 2025.
5
Primary perianal alveolar rhabdomyosarcoma with uncommon metastatic sites: a case report and follow-up using F-FDG PET/CT.原发性肛周肺泡横纹肌肉瘤伴不常见转移部位：1例病例报告及F-FDG PET/CT随访
Front Med (Lausanne). 2024 Dec 17;11:1474698. doi: 10.3389/fmed.2024.1474698. eCollection 2024.
6
Epidemiological trends and treatment abandonment of paediatric solid tumours in a nigerian tertiary hospital: a seven-year review (2016-2022).尼日利亚一家三级医院儿科实体瘤的流行病学趋势和治疗放弃情况：七年回顾（2016-2022 年）。
BMC Cancer. 2024 Aug 2;24(1):943. doi: 10.1186/s12885-024-12723-7.
7
Photoactive metabolite mediated photodynamic therapy of Rhabdomyosarcoma cell lines using medicinal plants and Doxorubicin co-treatments.采用药用植物和多柔比星联合治疗，用光活性代谢物介导横纹肌肉瘤细胞系的光动力疗法。
BMC Complement Med Ther. 2024 Jul 15;24(1):270. doi: 10.1186/s12906-024-04575-2.
8
Mechanisms Underlying the Rarity of Skeletal Muscle Cancers.骨骼肌癌罕见的潜在机制。
Int J Mol Sci. 2024 Jun 12;25(12):6480. doi: 10.3390/ijms25126480.
9
Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.CYP3A5 基因多态性与长春新碱在埃及儿科横纹肌肉瘤患者中的疗效和毒性。
Asian Pac J Cancer Prev. 2024 Apr 1;25(4):1391-1409. doi: 10.31557/APJCP.2024.25.4.1391.
10
Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside.当代小儿横纹肌肉瘤临床前小鼠模型：从床边到实验台再回到床边
Front Oncol. 2024 Feb 2;14:1333129. doi: 10.3389/fonc.2024.1333129. eCollection 2024.
本文引用的文献
1
Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.儿童肿瘤学组软组织肉瘤委员会的报告：对于新诊断的低危横纹肌肉瘤患者，采用长春新碱、放线菌素D和低剂量环磷酰胺进行短疗程治疗，联合或不联合放疗。
J Clin Oncol. 2014 Nov 1;32(31):3547-52. doi: 10.1200/JCO.2014.55.6787. Epub 2014 Sep 29.
2
Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.高危非转移性横纹肌肉瘤和其他化疗敏感型儿童软组织肉瘤的强化六药对比标准三药化疗的随机比较：国际儿科肿瘤学会 MMT95 研究的长期结果。
J Clin Oncol. 2012 Jul 10;30(20):2457-65. doi: 10.1200/JCO.2011.40.3287. Epub 2012 Jun 4.
3
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.帕唑帕尼治疗转移性软组织肉瘤（PALETTE）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16.
4
Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.横纹肌肉瘤：儿童肿瘤学组（COG）软组织肉瘤委员会经验回顾及当前 COG 研究的原理。
Pediatr Blood Cancer. 2012 Jul 15;59(1):5-10. doi: 10.1002/pbc.24118. Epub 2012 Feb 29.
5
18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models.18F-FDG 微 PET 成像检测到 IGF1R 抑制剂在基因工程横纹肌肉瘤模型中的早期短暂反应。
Pediatr Blood Cancer. 2012 Sep;59(3):485-92. doi: 10.1002/pbc.24075. Epub 2012 Jan 11.
6
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.儿童肿瘤组关于西妥昔单抗治疗难治性实体瘤和尤文肉瘤患儿的 I/II 期临床试验和药代动力学研究报告。
J Clin Oncol. 2012 Jan 20;30(3):256-62. doi: 10.1200/JCO.2011.37.4355. Epub 2011 Dec 19.
7
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.横纹肌肉瘤中间变性淋巴瘤激酶异常：临床和预后意义。
J Clin Oncol. 2012 Jan 20;30(3):308-15. doi: 10.1200/JCO.2011.37.8588. Epub 2011 Dec 19.
8
Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.低危横纹肌肉瘤低剂量放疗的局部控制：来自儿童肿瘤协作组 D9602 研究的报告。
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):720-6. doi: 10.1016/j.ijrobp.2011.06.2011. Epub 2011 Nov 19.
9
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.替西罗莫司治疗高级别胶质瘤、神经母细胞瘤和横纹肌肉瘤患儿的 II 期临床试验。
Eur J Cancer. 2012 Jan;48(2):253-62. doi: 10.1016/j.ejca.2011.09.021. Epub 2011 Oct 25.
10
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.甲磺酸艾日布林治疗软组织肉瘤患者的疗效：四种独立组织学亚型的 II 期研究。
Lancet Oncol. 2011 Oct;12(11):1045-52. doi: 10.1016/S1470-2045(11)70230-3. Epub 2011 Sep 19.
Zotero 插件